Insider · CIK 0001408239
N. V. Tyagarajan
Files at JBL (JABIL INC), G (Genpact LTD). First filing Nov 14, 2024, latest Aug 5, 2026.
In brief
N. V. Tyagarajan files SEC Form 4 as director at G (Genpact LTD), and also at JBL (JABIL INC). Since Nov 14, 2024, N. V. Tyagarajan has reported 1 open-market buy worth $150k and 2 open-market sells worth $6.1M, the latest filed on Aug 5, 2026.
A track record needs three past buys with six months of prices behind them; N. V. Tyagarajan has 0, so none is measured yet.
The newest scored trade: bought $150k of JBL on Jul 17, 2026, filed Aug 5, 2026, scored 33 (weak). In the last 12 months: 1 buy worth $150k and 0 sells worth $0.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
G: Genpact LTD
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
JBL: JABIL INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | JBLbuy JABIL INC | $150k 500 shares | +17% | +56% from low-22% from high | |
| 60Notable | Genpact LTD | $6.0M 108,880 shares | -15% | - | |
| 50Moderate | Genpact LTD | $93k 2,000 shares | -27% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Feb 18, 2025 | G Genpact LTD | 108,880 0.06% of outstanding | $6.0M | Feb 18, 2025 | none |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 17, 2026 | JBL JABIL INC | POpen-market purchase Common Stock | +500 | $299.63 | $150k | 3,464 | Aug 5, 2026 |
| Apr 23, 2026 | JBL JABIL INC | AGrant or award Common Stock | +600 | $0.00 | $0 | 2,964 | Apr 29, 2026 |
| Jan 23, 2026 | JBL JABIL INC | FTax withholding Common Stock | -147 | $244.70 | $36k | 2,364 | Jan 26, 2026 |
| Feb 18, 2025 | G Genpact LTD | SOpen-market sale Common Shares | -108,880 | $54.87 | $6.0M | 604,631 | Feb 20, 2025 |
| Jan 23, 2025 | JBL JABIL INC | AGrant or award Common Stock | +1,300 | $0.00 | $0 | 2,600 | Jan 27, 2025 |
| Jan 25, 2025 | JBL JABIL INC | FTax withholding Common Stock | -89 | $173.33 | $15k | 2,511 | Jan 27, 2025 |
| Jan 17, 2025 | G Genpact LTD | FTax withholding Common Shares | -47,972 | $43.34 | $2.1M | 713,511 | Jan 17, 2025 |
| Jan 10, 2025 | G Genpact LTD | FTax withholding Common Shares | -55,000 | $42.38 | $2.3M | 706,483 | Jan 14, 2025 |
| Nov 12, 2024 | G Genpact LTD | SOpen-market sale Common Sharesindirect: By Trust | -2,000 | $46.70 | $93k | 5,300 | Nov 14, 2024 |
Questions about N. V. Tyagarajan
Answered from the filings on this page, as of the latest one.
Is N. V. Tyagarajan buying or selling?
In the last 12 months N. V. Tyagarajan reported 1 open-market buy worth $150k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $150k of JBL on Jul 17, 2026. Grants, option exercises and tax withholding are not counted.
How did N. V. Tyagarajan's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and N. V. Tyagarajan has 0.
Where does N. V. Tyagarajan file Form 4?
N. V. Tyagarajan has filed Form 4 at G (Genpact LTD); JBL (JABIL INC). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.